The purpose of this study was to evaluate the efficacy and safety of bortezomib combined with CHEP in patients with peripheral T cell lymphoma. Primary end point of this study were objective response rate including complete remission rate and partial remission rate.
To evaluate the efficacy and safety of bortezomib combined with CHEP regimen in peripheral T cell lymphoma